$TAK · TAKEDA PHARMACEUTICAL CO LTD
Takeda filed its semi-annual securities report (6-K) for H1 FY2026 (April–September 2026). Revenue rose 8.4% AER to ¥2,407.0B, operating profit jumped 60.4% to ¥406.7B, and net profit attributable to owners surged 171.8% to ¥305.6B. The profit explosion was driven by a ¥118.3B drop in amortization/impairment charges and an 80.4% decline in income tax expenses from deferred tax benefits.
- Net profit attributable to owners soared 171.8% YoY to ¥305.6B (H1 FY2026) from ¥112.4B (H1 FY2025).
- Amortization and impairment losses on product intangibles fell 35.1% to ¥218.5B, including ¥69.8B lower impairment charges.
- Income tax expenses dropped 80.4% to ¥13.0B due to deferred tax asset recoverability reassessment and subsidiary restructuring benefits.
- Core revenue grew 8.4% AER to ¥2,407.0B but declined 1.0% on a constant-exchange-rate basis.
- ENTYVIO revenue rose 13.0% AER to ¥541.7B; restructuring expenses increased ¥52.4B from ongoing transformation program.
Extended-hours trading shows TAK at $20.67, up +2.58% vs the regular close of $20.15, suggesting a positive initial reaction to the sharp profit recovery.
The 172% net profit surge is largely non-operational (lower impairments, deferred tax benefits), while constant-currency core revenue actually contracted — a critical distinction for investors parsing the headline beat.
Takeda's results mirror the broader large-cap pharma playbook: favorable FX tailwinds from yen weakness boosting reported figures while constant-currency growth remains challenged, particularly outside GI and Oncology.
Core revenue declined 1.0% on a constant-exchange-rate basis, exposing underlying organic growth weakness masked by yen depreciation. Restructuring expenses surged ¥52.4B as the transformation program continues.